Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax plus ruxolitinib versus ruxolitinib in myelofibrosis
NL-OMON54363Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of navitoclax and ruxolitinib in myelofibrosis (MF), sponsored by AbbVie Inc. Started May 2021; status: completed.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON54363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54363.